Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Research into Cold Cancers Heating Up

Activation and expansion are essential for success in both autologous and allogeneic therapies.

Development of Gamma-Delta T-Cell Therapies

Continuous manufacturing and a quality-by-design development approach are a natural fit.

QbD for Small-Molecule Continuous Process Development

Topic

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

Articles

Kisunla (donanemab-azbt) reduced amyloid plaques in Phase III study participants by 84% after 18 months.

FDA Approves Lilly Treatment for Early Symptomatic Alzheimer’s Disease

Mike Hennessy Jr. is the Chairman and CEO of 

A greater number of patients with Duchenne muscular dystrophy will be able to be treated after FDA's approval of a gene therapy.

Publisher's Note: With Age Comes Wisdom

The company is referring to its search for innovative approaches as crowdsourcing and will award at least one cash prize.

Angelini Pharma Seeks Solutions for New Drug Delivery Systems and Treatments

Webcasts

Webinar Date/Time: Thu, Jul 25, 2024 11:00 AM EDT


Delving into Biopharmaceutical Development and Manufacturing

Life sciences data sets can be vast and complex to process, but up to now bringing intelligent automation systems up to speed and validating them has felt debilitatingly onerous. Large language models tackle these barriers head on. Ramesh Ramani and RaviKanth Valigari, technology innovators at ArisGlobal, explain.

Beyond GenAI: The Training-Free Discovery Potential of LLMs in a Drug Safety and Regulatory Context

The seven chosen sponsors will help accelerate development of novel drugs and biologics for rare diseases.

Participants for START Pilot Program Selected by FDA

Feliza Mirasol is the science editor for 

This acquisition will give AbbVie acces to Celsius Therapeutics' lead drug candidate, CEL383, a potential first-in-class anti-TREM1 antibody for treating IBD.

AbbVie Advances Inflammatory Disease Portfolio with Celsius Therapeutics Acquisition

Vabysmo, already approved for patients with RVO in the US and Japan, would be the first bispecific antibody treatment for the condition in Europe.

Roche Attains European Recommendation for Retinal Vein Occlusion Treatment

The typical cycle of ceasing and then reinitiating fremanezumab treatments may actually result in increased monthly migraine days, the study said.

Data from Study of Teva’s Ajovy Suggests Change to Migraine Treatment Pause Protocols

Johnson & Johnson gets two bispecific antibodies in early phase development for immune-mediated diseases through its Proteologix acquisition. 

Drug Development

Research into Cold Cancers Heating Up

Development of Gamma-Delta T-Cell Therapies

QbD for Small-Molecule Continuous Process Development